

ASGCT 25TH ANNUAL MEETING RECAP

May 16-19, 2022 I Washington, D.C.

ATTENDANCE IS GROWING!

2022: 7,614 total attendees

(66% in-person, 34% fully virtually)



2021: 6,864 attendees (fully virtual) 2020: 6,204 attendees (fully virtual) 2019: 4,503 attendees (in-person)

INTERNATIONAL PRESENCE



JOB LEVEL

35% Decision Maker for Organization

49% 10+ Years Professional

ORGANIZATION TYPE

67% Industry/Corporate19% Academic5% Non-profit5% Other

Government/Regulatory Agency

Top Industry Areas: #1: Pharmaceutical

and Clinical Stage Therapeutics

#2: Pre-Clinical

Therapeutics

PRIMARY ROLES

4%

51% Researcher/Scientist11% Executive/Organization Leader9% Business/Development

7% Other Corporate/Commercial

6% Student3% Physician

3% Regulatory Affairs Professional

2% Marketing/Sales

2% Non-Profit

2% Financial Investment

2% Patient Advocate

1% Gov. Relation/Market Access Professional

1% Other Healthcare Provider

1% N/A

EDUCATIONAL IMPACT AND PARTICIPATION

153 Speakers

336 Abstract Oral Presentations

896 Abstract Poster Presentations

18 Excellence in Research Awards

16 Industry Sponsored Symposia

12 Exhibitor Showcases

Tools & Technology Forum Presentations

6 Startup Showcases Presentations

170 Exhibitors

106 Sponsors

SOCIAL MEDIA AND PRESS

3,604+Posts using
Media
#ASGCT21
Registrants
Outlets

Featured Articles

<u>Gene therapy's comeback: how scientists are trying</u> to make it safer

<u>Francis Collins Urges Gene Therapy Community to</u> <u>Scale Efforts to Tackle Rare Diseases</u>

Even FDA's Peter Marks is worried about the commercial viability of gene and cell therapies

